Hong et al. (2022) found through in vitro and in vivo experiments that TP53 exon 7 mutations are associated with poorer overall survival (OS), TP53 exon 5 and 6 mutations are associated with poorer progression-free survival (PFS), and DLBCL with TP53 mutations is more susceptible to the effects of APR-246. APR-246 induces the accumulation of excess ROS, leading to ferroptosis and inhibiting tumor cell growth. Additionally, APR-246 has no significant toxicity in mice (Hong et al., 2022). This evidence concerns the gene TP53 and neoplasm.